
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer is expected to have a strong quarter and investers are focused on the company's key growth drivers, including Padcev, Nurtec, and Vyndamax as well as upcoming data readouts in oncology and obesity. They will also be looking for updates on the company's capital allocation and business development priorities, and management's ability to navigate the upcoming patent expiration. However, Pfizer's obesity candidates may not be as strong as competitors, and more derisking is needed to gauge the company's competitive profile and manufacturing and market access capabilities.
Bears say
Pfizer is facing several risks, including potential commercial execution issues with key products, disappointing clinical data or regulatory setbacks, and a slower growth profile compared to its peers. These risks, along with Pfizer's declining EBIT margins and a relatively stable revenue outlook, contribute to a negative outlook for the stock. Additionally, while the company has made efforts to improve leadership diversity, there are still concerns about limited representation at the C-suite level. All of these factors lead to a perception that Pfizer may face challenges in maintaining its current level of success, making it a high-risk investment.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares